Surgical margins must be clear of invasive carcinoma; if there is microscopic residual ductal in situ disease present at lumpectomy or total mastectomy margins, further excision is highly recommended; if further excision is not undertaken, the subject may still be entered on study, provided that in addition to breast or chest wall irradiation, a boost to the tumor bed is delivered; in situ lobular disease at the margin is acceptable
The patient must have undergone either a mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy
For patients who undergo mastectomy, the margins must be free of residual gross tumor; (patients with microscopic positive margins are eligible as long as post-mastectomy radiation therapy [RT] of the chest wall will be administered)
Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be completed within  days of the completion of the last dose of neoadjuvant chemotherapy
Breast surgery (lumpectomy or mastectomy) and sentinel lymph node surgery must be completed within  days of the completion of the last dose of neoadjuvant chemotherapy; negative margin (by either breast conservation or mastectomy) on final pathology where negative margin is defined as no tumor on ink
Must have completed definitive resection of primary tumor\r\n* Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however patients with positive margins may enroll if the treatment team believes no further surgery is possible and patient has received radiotherapy; patients with margins positive for lobular carcinoma in situ (LCIS) are eligible\r\n* Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable\r\n* Sentinel node biopsy either pre or post neoadjuvant chemotherapy (i.e. at the time of definitive surgery) are allowed; axillary dissection is encouraged in patients with lymph node involvement, but is not mandatory
Radiotherapy may be given before or after protocol treatment per standard of care guidelines; when radiotherapy is planned prior to protocol treatment administration, patients may be registered and screened while receiving radiation\r\n* Post-mastectomy radiotherapy is required for all patients with the following:\r\n** Primary tumor >=  cm (prior to neoadjuvant chemotherapy [clinically] or at the time of definitive surgery) or involvement of lymph nodes at the time of definitive surgery\r\n** For patients with primary tumors <  cm or without lymph node involvement prior to neoadjuvant chemotherapy and at the time of definitive surgery, provision of post-mastectomy radiotherapy is at the discretion of the treating physician\r\n** Radiation of regional nodal basins is at the discretion of the treating radiation oncologist\r\n* NOTE: Breast radiotherapy (whole breast or partial) is required for patients who underwent breast-conserving therapy, including lumpectomy or partial mastectomy
Patient who have undergone either a total mastectomy or a lumpectomy are eligible; (patients who have had a nipple-sparing mastectomy are eligible)
Completed adequate breast surgery defined as:\r\n* The inked margins of breast conservation surgery or mastectomy must be histologically free of invasive breast cancer and ductal carcinoma in situ with the exception of the posterior margin if this margin is the pectoralis major fascia or the anterior margin if this is the dermis; patients with resection margins positive for lobular carcinoma in situ are eligible\r\n* Patients with breast conservation must have adjuvant radiotherapy; patients having mastectomy may have adjuvant radiotherapy according to local policy and/or international guidelines
Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND
Women who have had a prior mastectomy (unilateral or bilateral), segmental mastectomy, reduction mammoplasty or breast augmentation including implants.
Diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy with any type of axillary surgery or axillary sampling
For patients who have undergone mastectomy, any type of mastectomy and any type of reconstruction (including no reconstruction) are allowed; metallic components of some tissue expanders may complicate delivery of proton therapy; any concerns should be discussed with the Breast Committee Study Chairs prior to registration
Must have had surgical treatment of the breast - either mastectomy or breast preserving surgery, such as lumpectomy. Re-excision of surgical margins is permitted.
Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer
Patients must have histologically confirmed invasive breast cancer (stages I-III) who have undergone core needle biopsy (clinically or radiographically at least Tc to allow adequate residual cancer tissue at surgery) and will be scheduled for surgical resection (i.e. segmental excision or mastectomy)
Undergone lumpectomy and/or mastectomy, are at  weeks from end of treatment with adjuvant chemotherapy or radiation and/or chemotherapy or are at a maximum of  years out from completion of such treatment;
Scheduled to undergo non-nipple sparing mastectomy for Invasive Breast Cancer or DCIS within  month
Subjects scheduled to undergo nipple sparing mastectomy
Breast cancer, stage -, deemed a surgically appropriate candidate for partial mastectomy with planned procedure for the same
Total mastectomy
Mastectomy intended
Breast surgery (lumpectomy or mastectomy) is planned for at least  days from the day of enrollment
Scheduled to undergo immediate, post-mastectomy, tissue assisted breast reconstruction, Reconstruction shall be either one-stage (direct-to-implant) or two-stage, unilateral or bilateral, prophylactic or therapeutic
Requiring Wise pattern reduction of mastectomy skin flap
Women scheduled for unilateral or bilateral mastectomy for breast cancer therapy, pathology confirmed stage -III (including ductal carcinoma in situ), or prophylaxis (BRCA/ mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected)
Willingness and ability to schedule mastectomy - days following start of study agent; women with breast implants may participate
Women receiving a nipple delay procedure prior to mastectomy
History of prior mastectomy
Patients who underwent partial excisional biopsy or lumpectomy, segmental mastectomy or modified radical mastectomy or sentinel node biopsy are not eligible
Bilateral prophylactic mastectomy
Patients must have histologically-confirmed stage IV TNBC (patients who had metastatic disease within  months of lumpectomy or mastectomy for treatment of TNBC may be excused from repeat biopsy)
Status post segmental mastectomy or mastectomy and axillary node dissection with removal of at least  nodes
Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy
Whole breast radiotherapy is required for patients who underwent breast conserving therapy, including lumpectomy or partial mastectomy. Patients receiving adjuvant radiation therapy must have completed radiotherapy at least  days prior to registration for protocol therapy.
Preference for mastectomy instead of breast-conserving surgery
Patients must not have had prior ipsilateral breast-conserving surgery or total mastectomy and be eligible for neoadjuvant treatment
Patient must be scheduled to undergo either a single or bilateral elective nipple-areola skin sparing mastectomy (NASSM) procedure with planned immediate reconstruction
Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy
Must have completed definitive resection of primary tumor. The most recent surgery for breast cancer must have been completed at least  days prior (but no more than  days prior) to study registration. NOTE: Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however participants with positive margins may enroll if the treatment team believes no further surgery is possible and patient has received radiotherapy. Participants with margins positive for lobular carcinoma in situ (LCIS) are eligible. Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable.
Whole breast radiotherapy is required for participants who underwent breast-conserving therapy, including lumpectomy or partial mastectomy. Participants must have completed radiotherapy at least  days prior (but no more than  days prior) to study registration.
Patients who underwent partial excisional biopsy, lumpectomy, segmental mastectomy, modified radical mastectomy or sentinel node biopsy and, therefore cannot be assessed for pathologic response accurately
Patients must have been treated by breast conserving surgery (BCS) or mastectomy
Diagnosis of early stage, invasive ductal carcinoma (for which a lumpectomy or mastectomy is planned prior to systemic therapy)
Patients with ductal carcinoma in situ undergoing either lumpectomy/radiation or mastectomy.
Negative inked histologic margins from mastectomy pathology (no invasive cells at margin)
Patient must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within  months after radiation
Has been treated with mastectomy
Has undergone immediate reconstructive surgery with placement of a tissue expander or permanent implant at time of mastectomy
Is a candidate for unilateral post?mastectomy radiation therapy as per National Comprehensive Cancer Network (NCCN) guidelines (post?mastectomy radiation therapy is indicated for most patients with positive lymph nodes at time of surgery and infrequently for selected node?negative patients)
Patients are having bilateral mastectomy
Patients will be excluded if they are having their mastectomy performed with tumescence
Undergoing lumpectomy (partial mastectomy) procedure
Have undergone a lumpectomy or mastectomy
Post lumpectomy or mastectomy
Undergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral therapeutic/contralateral prophylactic) planned to be exchanged for breast implants
Scheduled to undergo one of the following elective breast cancer surgery at Barnes-Jewish Hospital: axillary dissection, modified radical mastectomy, mastectomy with same day reconstruction, sentinel lymph node biopsy (SLNB), partial mastectomy with SLNB, or simple mastectomy with SLNB
Mastectomy type: skin-sparing or nipple-sparing mastectomy with or without sentinel lymph node biopsy; may be unilateral or bilateral mastectomy
Patients undergoing reconstruction after mastectomy (either implant or tissue based)
Participants will have completed surgery (lumpectomy or mastectomy) with or without neoadjuvant or adjuvant chemotherapy and with or without radiation
Received first breast surgery of total or partial mastectomy within the previous  months
Subjects are status post (s/p) breast surgical intervention, to include mastectomy, partial mastectomy, lumpectomy, or reconstruction
Women who have undergone a total mastectomy or breast-conserving surgery for primary breast cancer +/- chemotherapy, +/- radiotherapy
Patients who have had mastectomy with reconstructive surgery in one or both breasts
Mastectomy is the surgery performed
Status post mastectomy with surgical assessment of axillary nodes
Two discretionary enrollment criteria include:\r\n* Patients with ductal breast carcinoma in situ (DCIS) may be enrolled into the study if they are eligible for and considering either mastectomy or BCS with radiation\r\n* Patients taking neoadjuvant chemotherapy may be enrolled into the study if they are eligible for and considering either mastectomy or BCS
Participants will be diagnosed with breast cancer; the participants will be scheduled for a lumpectomy or a mastectomy at UH GMC Seidman Cancer Center
Subjects may or may not have had surgery (lumpectomy or mastectomy) prior to RT; (NOTE: surgery is not required for eligibility)
Patients undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon co-investigators are eligible for the study
Patients undergoing skin-sparing mastectomy utilizing bioprosthetic mesh are eligible for the study
Patients requiring additional intra-operative skin resections of greater than  cm beyond the skin edge as a result of mastectomy flap devascularization
Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions)
Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions) or combination of breast radiation and surgery involving both breasts
Patients who are treated for a medical condition (such as ulcerative colitis) with chronic steroids during the  years prior to planned mastectomy surgery
Women scheduled for mastectomy or lumpectomy after DCIS or ADH diagnosis
Women scheduled for unilateral or bilateral mastectomy for breast cancer therapy, pathology confirmed stage -II (including ductal carcinoma in situ), or prophylaxis (breast cancer , early onset [BRCA]/ mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected)
Willing and able to schedule mastectomy  weeks (+/- days) following start of study agent
Women receiving a nipple delay procedure prior to mastectomy
Have undergone a lumpectomy or mastectomy
Patients with inflammatory breast cancer are eligible for the escalation phase of the mastectomy cohort
Inflammatory breast cancer patients are ineligible, except in the escalation phase of the mastectomy cohort
Bilateral mastectomy
Surgery (mastectomy or BCT) planned within  days of the MRI
Patients undergoing a partial mastectomy OR mastectomy for the treatment of an invasive or non-invasive breast malignancy
Recommendation for mastectomy based on radiology
Patients scheduled to have a partial mastectomy or mastectomy for the treatment of breast cancer
Planned total mastectomy for treatment
Patients with a confirmed diagnosis of clinical stage  or  breast cancer who are undergoing breast cancer surgery with lumpectomy or mastectomy and planned axillary sentinel node biopsy procedure will be eligible for the study
Be scheduled for a biopsy (core/excisional/lumpectomy) of the mass or region of abnormality or for mastectomy within  days after this study procedure
Patients with DCIS or invasive breast cancer who are scheduled for a lumpectomy or mastectomy and are receiving surgical care from the Breast Surgery Department at Columbia Medical Center
Patient must have selected mastectomy for surgical option of treatment
Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast
Stage I-IIIc disease:\r\n* Scheduled for lumpectomy or mastectomy\r\n* No prior or current therapy for breast cancer\r\n* Not considered candidate for therapeutic neoadjuvant treatment
Patient: Had a mastectomy for breast cancer no more than  years prior to enrollment
Surgeon: Performs breast reconstruction procedures after mastectomy
Considering a mastectomy
Only women considering mastectomy will be eligible; that is, women who have definitely selected lumpectomy will not be approached
Adult women with breast cancer who have undergone surgery for their primary breast tumor (either lumpectomy or mastectomy +/- reconstruction) and are confirmed to have involved lymph nodes on surgical pathology